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Abstract 
Purpose of review: 
Anti-neutrophil cytoplasmic antibodies (ANCA) remain central to our current 
understanding of the pathogenesis of ANCA-associated vasculitis (AAV), and this 
review considers recent developments in the context of four key questions: (1) are 
there targets for ANCA beyond myeloperoxidase (MPO) and proteinase 3 (PR3); (2) 
are all ANCA pathogenic; (3) how are ANCA generated; and (4) how do ANCA cause 
disease? 
Recent findings: 
B-cell epitope mapping raises the possibility that only a subset of ANCA may be 
pathogenic. Anti-LAMP-2 autoantibodies have recently emerged as novel form of 
ANCA, and can be found in anti-MPO and anti-PR3-negative disease. These also 
provide recent evidence for molecular mimicry in the pathogenesis of AAV, but 
definitive proof in human AAV remains elusive. Neutrophil extracellular traps may 
represent an important mechanism by which MPO and PR3 are taken up by 
dendritic cells for presentation to the adaptive immune system, and the role of the 
alternative pathway of complement in AAV has recently been emphasized, with 
therapeutic implications. 
Summary: 
Our current understanding of the pathogenesis of AAV reinforces the central role of 
neutrophils, but also provides a sound rationale for B-cell and complement-directed 
therapies. 




Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 
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Introduction 
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-
threatening, small vessel vasculitis characterized by the presence of pathogenic anti-
proteinase 3 (PR3) and anti-myeloperoxidase (MPO) autoantibodies and renal, lung 
and upper respiratory tract involvement. Clinically and pathologically, three forms 
are traditionally recognized: granulomatosis with polyangiitis (GPA, formerly 
Wegener’s granulomatosis), which is distinguished by necrotizing granulomas on 
biopsy and frequent upper respiratory tract involvement; microscopic polyangiitis 
(MPA); and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-
Strauss Syndrome), which is much less common and distinguished by a prominent 
eosinophilia and allergic features.[1] There is significant clinical and pathological 
overlap between these diseases, and evidence is accumulating that sub-classification 
of AAV using ANCA antigen specificity may better reflect both prognosis and disease 
pathogenesis than traditional clinical definitions, reinforcing that fundamentally 
AAV remains an ANCA-centric disease.[2–4] This review, therefore, considers 
current research in the context of four key questions: (1) are there targets for ANCA 
beyond MPO and PR3; (2) are all ANCA pathogenic; (3) how are ANCA generated; 
and (4) how do ANCA cause disease? 
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Are there targets for ANCA beyond myeloperoxidase and proteinase-3, and are all 
ANCA pathogenic? 
ANCA were first recognized for their ability to label neutrophils by indirect 
immunofluorescence.[5] The staining conformed to two patterns: perinuclear, and 
cytoplasmic, and MPO and PR3 were soon identified as their predominant target 
autoantigens, respectively. Multiple additional targets of ANCA were identified 
during the 1990s, including cathepsin-G and neutrophil elastase,[6] but these lack 
the specificity and the associated evidence of pathogenicity that has since 
accumulated for anti-PR3 and anti-MPO ANCA. The latter ranges from a case report 
of neonatal vasculitis in the context of exposure to maternal anti-MPO ANCA to 
evidence of glomerulonephritis after passive transfer of anti-MPO and anti-PR3 
ANCA in murine models of disease.[7–9] On the other hand, there are also numerous 
examples of detectable anti-MPO and anti-PR3 ANCA in otherwise healthy 
individuals or individuals with a range of non-vasculitic diseases (e.g. systemic 
lupus erythematosus (SLE), ulcerative colitis), which demonstrates that ANCA are 
not always pathogenic.[10,11] In addition, up to a third of patients with a clinical 
diagnosis of AAV are ANCA-negative by conventional assays,[6] suggesting there 
may be additional targets for autoantibodies. 
 
The question of ANCA specificities and pathogenicity has been addressed by recent 
studies. Using a mass spectrometry-based approach, Roth and colleagues identified 
25 epitopes bound by anti-MPO autoantibodies.[12] Autoantibodies binding one of 
the linear epitopes, MPO447-459, were exclusively found in patients with active 
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disease, suggesting that these autoantibodies may be pathogenic. This was 
supported by evidence that ANCA binding this epitope activated neutrophils in vitro 
and by the observation that DR2 transgenic mice immunized with the 
corresponding murine epitope developed a pauci-immune glomerulonephritis. 
However, complicating this, these immunized mice developed a polyclonal anti-MPO 
ANCA that bound a range of epitopes including but not limited to the MPO447-459. The 
remaining MPO epitopes were classified according to whether they bound ANCA 
from patients with active disease, remission or healthy volunteers, and this was 
used as a basis to infer potential pathogenicity. However, where ANCA were 
detectable in healthy volunteers, it was at extremely low levels. It remains unclear, 
therefore, whether ANCA targeting these epitopes are truly non-pathogenic at the 
higher concentrations observed in disease. 
 
The same study also found that purified immunoglobulin from patients with ANCA-
negative disease was able to bind the pathogenic MPO447-459 epitope, implying that 
detection of ANCA in a proportion of ANCA-negative patients may be masked by a 
serum factor (perhaps a fragment of ceruloplasmin) interfering with standard 
assays. Larger studies are needed to validate these findings and determine the 
proportion of ANCA negative patients accounted for by this proposed mechanism. 
 
There are other potential mechanisms for ANCA-negative vasculitis. Espéli and 
colleagues have demonstrated that most auto-antibody producing plasma cells in 
mice with active SLE are found in inflammatory lesions, suggesting local production 
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of autoantibodies might help drive disease[13]; this potential mechanism has not 
been investigated in ANCA-negative AAV. Studies of anti-LAMP-2 autoantibodies 
performed by Kain and colleagues also suggest that these may represent a novel 
form of ANCA present in anti-PR3 and anti-MPO ANCA-negative disease. LAMP-2, a 
lysosomal membrane protein, was first identified as an antigenic target of ANCA in 
1995 as part of a broader screen.[14] Follow-up publications in 2008 and 2012 
reported that anti-LAMP-2 autoantibodies were widely present in patients with 
ANCA-positive vasculitis (14/16 patients in the 2008 study and 78/84 patients in 
2012), coexisting with anti-MPO or anti-PR3 in most cases. These studies were not 
without controversy: the complex, highly glycosylated nature of native LAMP-2 
meant that assays for anti-LAMP-2 antibodies were difficult to replicate,[15,16] 
however Kain argues plausibly that this is due to differences in patient selection 
(anti-LAMP-2 antibodies are sensitive to immunosuppression and disease activity) 
and the source of LAMP-2 antigen used.[17] More recently, anti-LAMP2 antibodies 
were found in eight of eleven ANCA-negative patients presenting with a pauci-
immune glomerulonephritis.[18*] These autoantibodies were notable for binding 
the less-glycosylated glomerular form of LAMP-2, not the highly-glycosylated 
neutrophil form. Evidence for the pathogenicity of anti-LAMP-2 autoantibodies 
comes from their association with disease in animal models and their correlation 
with active disease in the human studies discussed above. Animal models include a 
2013 Japanese study in which transgenic rats overexpressing the human T-cell 
lymphocyte virus type 1 gene env-pX  develop a cutaneous vasculitis and 
spontaneous anti-LAMP-2 autoantibodies (without anti-PR3 or anti-MPO 
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ANCA).[19] When these antibodies were transferred into disease-free env-pX rats 
they progressed to develop an accelerated neutrophil-rich cutaneous vasculitis in 
comparison to non-treated control rats. The same study also identified anti-LAMP-2 
autoantibodies in a subset of patients with cutaneous polyarteritis nodosa, and with 
Henoch-Schonlein purpura, diseases not classically associated with ANCA. This 
implies that, as with anti-MPO and anti-PR3 ANCA, anti-LAMP-2 autoantibodies may 
not wholly specific for AAV. 
 
Antibodies targeting moesin have also recently been described in a Japanese cohort 
of patients with anti-MPO AAV with some capacity to stimulate monocytes and 
neutrophils in vitro.[20] 
 
 
How are ANCA generated? 
Multiple hypotheses have been presented for the formation of ANCA, with molecular 
mimicry one of the most discussed. However, a pathogen may contribute to the risk 
of autoimmunity without necessarily being present at the onset of that disease (the 
so-called ‘fertile field’ hypothesis),[21] which makes establishing its role 
particularly challenging. Yet there is increasing evidence of heterologous immune 
responses to multiple pathogens making molecular mimicry a plausible 
hypothesis.[22] The most convincing evidence for its role in AAV comes from 
homology between FimH, a component of type 1 fimbriae found on a range of gram-
negative pathogens, and LAMP-2.[23] Here, rats immunized with FimH progressed 
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to develop cross-reactive anti-LAMP-2 antibodies and a pauci-immune 
glomerulonephritis. 
 
Another hypothesis is that homology between certain Staphylococcus aureus 
proteins and a peptide encoded by the reverse DNA strand to PR3 (‘complementary’ 
PR3, cPR3) results in an immune response to S. aureus generating antibodies that 
are also cross-reactive with cPR3.[24] These anti-cPR3 autoantibodies are then said 
to seed the development of idiotypic, PR3-reactive antibodies, ultimately leading to 
the development of clinical GPA. However, there is no direct evidence that anti-cPR3 
antibodies cross-react with bacterial proteins, and others have not been able to 
confirm the presence of elevated anti-cPR3 antibody titres in GPA, nor establish a 
relationship between the presence of anti-cPR3 antibodies and S. aureus 
carriage.[25] 
 
Nonetheless, an association between S. aureus carriage and AAV is well 
described,[26] and a role for S. aureus in the pathogenesis of AAV continues to be 
sought. Potential mechanisms include the ability of S. aureus to potently induce the 
formation of neutrophil extracellular traps (NETs),[27] discussed below or, more 
generally, bacterial activation of neutrophils through the activation of toll-like 
receptors. TLR4 and TLR9, whose ligands are gram-positive bacterial components 
and bacterial DNA respectively, have been shown to trigger MPO release and 
increased surface expression of PR3.[28] A recent candidate gene study has also 
identified polymorphisms at the TLR9 locus as modulating susceptibility to GPA.[29] 
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This circumstantial evidence suggests a plausible mechanism by which S. aureus 
could drive GPA, but is remains far from conclusive. 
 
Non-infectious triggers for ANCA formation have been described. Medications are 
chief among these and include levamisole (used as a ‘cutting’ agent for cocaine), one 
of the few instances in which both anti-PR3 and anti-MPO autoantibodies coexist, 
and propylthiouracil as recently reviewed in [30]. 
 
A role for T-cells in the generation of ANCA is suggested by their high affinity, class-
switched nature and underscored by long-reported associations between MHC class 
II variants and AAV.[31,32] Recent GWAS studies have begun to define the latter 
more closely. Anti-MPO AAV and anti-PR3 AAV were strongly associated with HLA-
DQ and HLA-DP variants, respectively.[3] The HLA-DP association was replicated in 
a second AAV GWAS, likely driven by the high anti-PR3 prevalence in this 
predominantly GPA cohort.[32] Precisely how a specific HLA risk allele predisposes 
to autoimmunity in AAV has not been determined, but in other diseases with a Class 
II HLA association it has been possible to map the genetic association onto key 
amino acid residues in the peptide-binding groove.[33] The ability of these HLA risk 
alleles to specifically bind peptides that have undergone post-translational 
modification seems to be an important property that may predispose to 
autoimmunity.[34] 
 
Final  14 November 2014 
 11 
What has also become clear is that the generation of ANCA may be facilitated by 
positive feedback loops within the innate immune system whereby, for example, 
ANCA stimulates the formation of NETs and which then facilitate the further 
generation of ANCA. These are discussed further in the next section, which examines 
recent developments in some of the effector pathways downstream of ANCA. 
 
How do ANCA cause disease? 
Recent research into the role of NETs and complement in AAV has added 
significantly to our understanding of how ANCA cause disease. 
Neutrophil extracellular traps, and their role in AAV 
A unique feature of neutrophils, which are key players in AAV, is their ability to 
generate NETs, a ‘sticky mesh’ of extruded chromatin, nucleic acid and a range of 
cytoplasmic proteins. These serve antibacterial functions, but also represent a 
means by which cytoplasmic proteins may be exposed to the immune system.[35] In 
2009, AAV was one of the first autoimmune diseases to be linked to excessive NET 
formation.[36] This initial study demonstrated that NETs contain MPO and PR3 and 
are induced by ANCA. Moreover, extracellular DNA, histones and neutrophil granule 
components including PR3 and MPO co-localised in the glomeruli of patients with an 
active ANCA-associated glomerulonephritis, placing NETs at the site of tissue 
damage in vivo. Since then, increasing circumstantial evidence suggests that NETs 
represent an important means for autoantigen uptake by antigen presenting cells 
(APCs) in AAV. First, Sangaletti and colleagues showed in an elegant study that 
Final  14 November 2014 
 12 
murine NETs specifically interact with myeloid dendritic cells (mDCs) to facilitate 
the uptake of MPO and PR3. Moreover, when these NET-cultured mDCs were then 
transferred into healthy mice both new ANCA formation and an active 
glomerulonephritis were observed,[37] although exactly how an interaction with 
NETs licenses APCs to provide enhanced costimulation to B- and T-cells in 
subsequent interactions is unclear. Recent human studies provide additional 
evidence for the importance of NETs in AAV, showing that that the serum of patients 
with MPO+ vasculitis potently induces NET formation and retards their degradation, 
the latter potentially through an inhibitory action of anti-NET antibodies.[38*] It is 
hypothesized, but remains to be proven, that excessive or inappropriate NET 
formation or delayed NET degradation represents an important mechanism by 
which the key AAV autoantigens MPO and PR3 are taken up by APCs in a pro-
inflammatory context for presentation to B- and T-cells (figure 1). 
Complement 
Our understanding of the role of complement in tissue damage in AAV has also 
undergone a substantial shift. The pauci-immune nature of the characteristic lesions 
had given rise to an initial belief that complement did not play a significant role in 
AAV pathogenesis.[39] Since then, a number of studies have convincingly shown 
that activation of the alternative pathway of complement and an intact C5a receptor 
(C5aR) are necessary for the development of glomerulonephritis in murine models 
of vasculitis, prompting a re-assessment of the role of complement in human 
AAV.[40,41] Experiments in vitro showed that ANCA-stimulated healthy human 
neutrophils are able to activate complement and that complement acting through 
Final  14 November 2014 
 13 
the C5aR is able to prime neutrophils and upregulate PR3 surface expression.[42] 
Moreover, C3F, a common coding genetic variant of C3, was found to be 
overrepresented in patients with AAV in small candidate gene studies.[43–45] 
Despite the pauci-immune tag, a number of studies have also demonstrated low 
level glomerular immune-complex deposition, including complement 
components.[46,47] 
 
A Chinese group reported that complement deposition in renal biopsies of AAV 
patients correlated with worse renal injury, and that glomerular deposition and 
urine levels of the alternative pathway complement fragment Bb, in particular, 
correlate well with AAV activity. [48*] Other complement components including 
C3a, C5a and soluble C5b-9 were also found to be elevated and, separately, they 
reported increased plasma levels of activated complement components C3a, C5a 
and Bb in patients with active AAV.[49] C5aR (CD88) expression in renal biopsy 
specimens was predominantly tubular, was reduced in active vasculitis and absent 
on infiltrating glomerular neutrophils, raising questions about the importance of 
this receptor in AAV.[50] However, given that C5aR on neutrophils is internalized 
upon activation, and cleaved by neutrophil serine proteases from the surface of 
other cell types, this is not necessarily inconsistent with a role for C5aR in AAV.[51] 
Taken together these observations support a role for the alternative pathway of 
complement in human AAV, consistent with the murine data. An inappropriate 
positive feedback loop in which ANCA-activated neutrophils themselves activate 
complement, further increasing the amount of C5a present, may be important in 
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sustaining the inflammatory process (figure 2). These observations, especially if 
replicated, provide a rationale for the use of eculizumab, a C5a inhibitor, in AAV, 
with a preliminary report providing an early suggestion of clinical efficacy.[52] 
 
Other notable recent findings – in brief 
Under certain conditions it is clear that B cells can have a regulatory function, driven 
at least in part by the production of IL-10. These “regulatory B-cells” can be hard to 
define phenotypically, and there is only limited evidence that they comprise a 
distinct “lineage”. Four small recent clinical studies suggest that in AAV, especially 
GPA, a sub-population of B cells retains an ability to produce IL-10 and suppress T-
cell differentiation and proliferation, but is reduced in number.[53–56] Further 
work is needed to clarify the role of B-cell regulation of AAV, however, as these 
changes may be secondary to changes in effector populations, and none of the 
studies established a convincing dose relationship between AAV disease activity and 
these cells. Regulatory T-cells (Tregs) also have the capacity to suppress immune 
responses. Studies of Treg populations in AAV are conflicting, and there is no 
consensus regarding changes in their suppressive ability or the size of the T-reg 
population in active disease.[57–59]. The most recent study to examine their role in 
AAV enrolled 62 patients in a cross-sectional fashion, finding that during active 
disease this population was expanded relative to other CD4+ T-cell populations but, 
again, it is difficult to know whether this is secondary to changes in the effector 
compartment given that the controls were paired remission samples and healthy 
volunteers.[60] 
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Conclusions 
In the last few years, some controversies in the pathogenesis of AAV have moved 
closer to resolution but others remain hotly debated. NETs have emerged as a likely 
mechanism by which MPO and PR3 are taken up by APCs for presentation to the 
adaptive immune system, but the precise mechanisms by which tolerance to these 
self-antigens is broken remains unclear. Molecular mimicry remains an attractive 
hypothesis, and the most convincing evidence for this comes from controversial 
studies into the development of anti-LAMP-2 autoantibodies. Recent publications 
suggest an increasing acceptance of their role in AAV, but further research is 
needed. Large-scale genetics studies have identified a number of loci, including MHC 
Class II, that confer genetic susceptibility to AAV, and an important topic for future 
research will be determining how polymorphisms at these loci contribute to disease 
pathogenesis. An increasing appreciation of the importance of complement in 
generating tissue inflammation in AAV underscores the exciting potential of the 
complement pathway inhibitor eculizumab as a novel therapeutic for active disease. 
This demonstrates that the difficult process of teasing out the key pathogenic 
features driving AAV can provide real patient benefit. 
 
Key Points: (3-5 bullet points) 
 Emerging evidence suggests that epitope specificity may contribute to the 
pathogenicity of anti-neutrophil cytoplasmic antibodies (ANCA), and that anti-
LAMP-2 antibodies represent a novel form of ANCA. 
 The alternative pathway of complement is increasingly recognized as being 
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important in mediating the pathogenicity of ANCA. 
 Neutrophils remain central to the pathogenesis of ANCA-associated vasculitis, 
with neutrophil extracellular traps playing a potentially important role in 
initiating the immune response. 
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Figure titles and legends: 
Figure 1. 
Excessive neutrophil extracellular trap (NET) formation promotes the development 
of ANCA by allowing uptake of MPO and PR3 by antigen presenting cells (APC) in a 




Activation of the alternative complement pathway results in the generation of C5a, 
which exerts a broad range of downstream effects on neutrophils through the 
ligation of its receptor, C5aR, including the further generation of complement in a 
positive feedback loop. 
 
 
 
